Tech Company Financing Transactions
Carmine Therapeutics Funding Round
Cystic Fibrosis Foundation, EVX Ventures and Huagai Capital participated in a Series A capital raise for Carmine Therapeutics. The financing round was announced by the company on 10/13/2022.
Transaction Overview
Company Name
Announced On
10/13/2022
Transaction Type
Venture Equity
Amount
Unknown
Round
Series A
Proceeds Purpose
The company plans to use the Series A funding to advance development of its first set of programs in retinal and pulmonary diseases toward the clinic.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
150 CambridgePark Dr 701
Cambridge, MA 02140
USA
Cambridge, MA 02140
USA
Phone
Undisclosed
Website
Email Address
Overview
Our vision is to make genetic medicines broadly accessible to address the unmet medical needs of patients. Carmine Therapeutics is an EVX Ventures company that is headquartered in Cambridge, Massachusetts. We are pioneering powerful new genetic medicines that are based on red blood cell extracellular vesicles (RBCEVs). Our proprietary Red Cell EV Gene Therapy (REGENT®) platform generates a pipeline of next-generation disease-modifying gene therapies for a broad spectrum of diseases.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Don Haut
Vice President
Ozan Alkan
Vice President
John Robblee
Vice President
Qin Yu
Browse more venture capital transactions:
Prev: 10/13/2022: Otterspace venture capital transaction
Next: 10/13/2022: Odyssey Therapeutics venture capital transaction
Share this article
Where The Data Comes From
Our team works diligently to report on every notable VC transaction. VC transactions on this site are sourced from news reports and company announcements. The information comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs